Neuromuscular transmission deficits in patients with CMT and ClC ‐1 inhibition in CMT animal models
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.52252 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Thomas Skjærlund Grønnebæk und 14 weiteren Autor:innen. Beteiligte Einrichtung: NMD Pharma A/S, Aarhus, Denmark. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Neuromuscular Junction, Chloride Channels, Synaptic Transmission. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Charcot–Marie Tooth (CMT) is a hereditary neuropathy characterized by muscle weakness and fatigue with no approved therapies. Preclinical studies implicate neuromuscular junction (NMJ) transmission deficits in muscle dysfunction in CMT. This study aimed to evaluate NMJ function in patients with CMT types 1 and 2, and to determine whether enhancing NMJ transmission can improve muscle function in preclinical CMT models.
Methods
First, an observational study involving single fiber electromyography (SFEMG) and clinical testing in patients with CMT 1 and 2 and healthy controls (HC) was conducted. Next, preclinical studies examined muscle function, specifically nerve‐stimulated muscle force after partially inhibiting ClC‐1 chloride channels with the novel small molecule NMD670.
Results
Twenty‐one CMT patients (46.4 ± 14.4 years) and 10 HC (43.3 ± 12.7 years) were enrolled. SFEMG jitter (NMJ variability) was higher [median (range)] in the CMT patients [56 μs (35; 197 μs)] vs. HC [29 μs (19; 36 μs)], ( p < 0.05). Blocking (NMJ failure) was higher in the CMT patients (13.4% (0.0; 90.9%)) vs. HC (0.0% (0.0; 4.5%)), ( p < 0.05). In CMT, jitter and blocking correlated inversely with muscle strength, mobility, balance, and endurance. In CMT 1A and 2D mice, NMD670 increased both peak force and contractile endurance in vivo.
Interpretation
Our study suggests that NMJ dysfunction contributes to muscle dysfunction in patients with CMT 1 and 2. Furthermore, our preclinical data provide proof‐of‐mechanism for recovery of muscle function with ClC‐1 inhibition in CMT mouse models. Collectively, these findings suggest that targeting NMJ dysfunction with ClC‐1 inhibitors could enhance muscle function in CMT patients, warranting further clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- NMD Pharma A/S, Aarhus, Denmark.
- Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
- NextGen Precision Health, University of Missouri, Columbia, Missouri, USA.
- Department of Physical Medicine and Rehabilitation, University of Missouri, Columbia, Missouri, USA.
- Department of Neurology, The Ohio State University, Columbus, OH, USA.
- Department of Biomedicine, Aarhus University, Aarhus, Denmark.
ORCID-Profile: Martin Skov, Kristina Kelly, Hatice Tankisi, William David Arnold
Zitieren
APA
Grønnebæk, T. S., Haahr-Lillevang, H., Skov, M., Kelly, K., Kerr, N. R., Viteri, J. A., Jaworek, A., Bartlett, A., Bold, J., Hutchison, J., Quiroz, J., Tankisi, H., Pedersen, T. H., Andersen, H., & Arnold, W. D. (2025). Neuromuscular transmission deficits in patients with CMT and ClC ‐1 inhibition in CMT animal models. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52252
Vancouver
Grønnebæk TS, Haahr-Lillevang H, Skov M, Kelly K, Kerr NR, Viteri JA, et al. Neuromuscular transmission deficits in patients with CMT and ClC ‐1 inhibition in CMT animal models. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.52252
BibTeX
@article{Grnnebk2025,
author = {Grønnebæk, Thomas Skjærlund and Haahr-Lillevang, Helga and Skov, Martin and Kelly, Kristina and Kerr, Nathan R and Viteri, Jose A and Jaworek, Andrea and Bartlett, Amy and Bold, Jane and Hutchison, John and Quiroz, Jorge and Tankisi, Hatice and Pedersen, Thomas Holm and Andersen, Henning and Arnold, William David},
title = {Neuromuscular transmission deficits in patients with CMT and ClC ‐1 inhibition in CMT animal models},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.52252}
}
EUVIMED